{"transactions":[{"id":846466,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-12T20:25:23.000Z","date":"2026-03-11","kind":"sale","planned":false,"acquired":false,"shares":446,"price":31.23,"value":13928.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-104239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526104239/ownership.xml","form_type":"4"}},{"id":846465,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-12T20:25:23.000Z","date":"2026-03-11","kind":"sale","planned":false,"acquired":false,"shares":44173,"price":30.41,"value":1343300.93,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":10806,"source":{"system":"sec-edgar","filing":"0001193125-26-104239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526104239/ownership.xml","form_type":"4"}},{"id":851340,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2026-03-11T00:58:01.000Z","date":"2026-03-09","kind":"other","planned":false,"acquired":false,"shares":44619,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2022-12-22","expiration_date":"2027-11-23","underlying":"Ordinary Shares","underlying_shares":44619},"source":{"system":"sec-edgar","filing":"0001193125-26-100798","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526100798/ownership.xml","form_type":"4"}},{"id":851339,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-11T00:58:01.000Z","date":"2026-03-09","kind":"other","planned":false,"acquired":true,"shares":44619,"price":11.5,"value":513118.5,"ownership":{"direct":true},"balance_after":54979,"source":{"system":"sec-edgar","filing":"0001193125-26-100798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526100798/ownership.xml","form_type":"4"}},{"id":851338,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-03-11T00:58:01.000Z","date":"2026-03-06","kind":"sale","planned":false,"acquired":false,"shares":28186,"price":29.41,"value":828950.26,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by LGLange III Trust DTD10 (the \"Trust\") for the benefit of the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-100798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526100798/ownership.xml","form_type":"4"}},{"id":942359,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2026-01-10T00:33:10.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."}],"balance_after":15300,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001193125-26-009268","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009268/ownership.xml","form_type":"4"}},{"id":942358,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-10T00:33:10.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2026 for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of RSUs on March 28, 2025 to his direct holdings. Such ordinary shares are held directly by LGLange III Trust DTD10 for the benefit of the Reporting Person. The Reporting Person subsequently corrected his indirect holdings on April 21, 2025, and the Reporting Person's indirect holdings reported on May 2, 2025 and June 3, 2025 are correct. This Form 4 reflects the Reporting Person's correct direct holdings."}],"balance_after":10360,"source":{"system":"sec-edgar","filing":"0001193125-26-009268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526009268/ownership.xml","form_type":"4"}},{"id":1125457,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-03T20:59:38.000Z","date":"2025-06-01","kind":"exercise","planned":false,"acquired":false,"shares":68,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the \"Closing Date\"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":68},"source":{"system":"sec-edgar","filing":"0000950170-25-081072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025081072/ownership.xml","form_type":"4"}},{"id":1125456,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-06-03T20:59:38.000Z","date":"2025-06-01","kind":"exercise","planned":false,"acquired":true,"shares":68,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by LGLange III Trust DTD10 (the \"Trust\") for the benefit of the Reporting Person."}],"balance_after":28186,"source":{"system":"sec-edgar","filing":"0000950170-25-081072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025081072/ownership.xml","form_type":"4"}},{"id":1161342,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-02T20:55:45.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":false,"shares":69,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the \"Closing Date\"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025 and 69 RSUs vested on May 1, 2025. The 68 remaining RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer as of each of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025 and 69 RSUs vested on May 1, 2025. The 68 remaining RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer as of each of the vesting date."}],"balance_after":68,"derivative":{"underlying":"Ordinary Shares","underlying_shares":69},"source":{"system":"sec-edgar","filing":"0000950170-25-062894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025062894/ownership.xml","form_type":"4"}},{"id":1161341,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-05-02T20:55:45.000Z","date":"2025-05-01","kind":"exercise","planned":false,"acquired":true,"shares":69,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by LGLange III Trust DTD10 (the \"Trust\") for the benefit of the Reporting Person."}],"balance_after":28118,"source":{"system":"sec-edgar","filing":"0000950170-25-062894","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025062894/ownership.xml","form_type":"4"}},{"id":1168486,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-04-21T21:41:13.000Z","date":"2025-04-14","kind":"exercise","planned":false,"acquired":false,"shares":69,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"3,102 RSUs vested upon grant and 69 RSUs vested on April 1, 2025. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the issuer as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on May 1, 2025 and 68 of the remaining RSUs will vest on June 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"3,102 RSUs vested upon grant and 69 RSUs vested on April 1, 2025. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the issuer as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on May 1, 2025 and 68 of the remaining RSUs will vest on June 1, 2025."}],"balance_after":137,"derivative":{"underlying":"Ordinary Shares","underlying_shares":69},"source":{"system":"sec-edgar","filing":"0000950170-25-056395","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025056395/ownership.xml","form_type":"4"}},{"id":1168485,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-04-21T21:41:13.000Z","date":"2025-04-14","kind":"exercise","planned":false,"acquired":true,"shares":69,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by LGLange III Trust DTD10 (the \"Trust\") for the benefit of the Reporting Person. The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of restricted stock units (\"RSUs\") on March 28, 2025 to his direct holdings. Such ordinary shares are held by the Trust, and this Form 4 reflects the Reporting Person's correct direct and indirect holdings."}],"balance_after":28049,"source":{"system":"sec-edgar","filing":"0000950170-25-056395","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025056395/ownership.xml","form_type":"4"}},{"id":1188945,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:24:45.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":false,"shares":3102,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025."}],"balance_after":206,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3102},"source":{"system":"sec-edgar","filing":"0000950170-25-046958","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046958/ownership.xml","form_type":"4"}},{"id":1188944,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:24:45.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":3308,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025."}],"balance_after":3308,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3308},"source":{"system":"sec-edgar","filing":"0000950170-25-046958","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046958/ownership.xml","form_type":"4"}},{"id":1188943,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:24:45.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":true,"shares":3102,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10062,"source":{"system":"sec-edgar","filing":"0000950170-25-046958","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046958/ownership.xml","form_type":"4"}},{"id":1306916,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2025-01-08T22:57:58.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3 of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date."}],"balance_after":32500,"derivative":{"exercise_price":25.85,"expiration_date":"2035-01-06","underlying":"Ordinary Shares","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000950170-25-003552","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025003552/ownership.xml","form_type":"4"}},{"id":1306915,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-01-08T22:57:58.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":6960,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2025 for no consideration."}],"balance_after":6960,"source":{"system":"sec-edgar","filing":"0000950170-25-003552","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025003552/ownership.xml","form_type":"4"}},{"id":1629780,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-02-21T22:00:25.000Z","date":"2024-02-13","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":19,"value":95000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents ordinary shares acquired from the Company in an underwritten public offering. The ordinary shares acquired from the Company were placed into and are being held in a trust account for the benefit of the Reporting Person."}],"balance_after":24878,"source":{"system":"sec-edgar","filing":"0000950170-24-018045","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024018045/ownership.xml","form_type":"4"}},{"id":1693374,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-01-03T22:17:36.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":11.17,"expiration_date":"2034-01-01","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-24-001128","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024001128/ownership.xml","form_type":"4"}},{"id":3310828,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":16200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3310827,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":38.65,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3310826,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Reflects the correct exercise price of this option.  The exercise price of this option was previously reported as $26.01."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":26.15,"expiration_date":"2027-10-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3310825,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"disposition_to_issuer","acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":15.03,"expiration_date":"2026-08-24","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3310824,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"other","acquired":false,"shares":3555,"price":60,"value":213300.0,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust("},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3310823,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"other","acquired":false,"shares":32343,"price":60,"value":1940580.0,"ownership":{"direct":false,"nature":"By Asset Management Ventures Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is a general partner of Asset Management Ventures Fund, L.P. (\"AMVF L.L.P.\"), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3310822,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"other","acquired":false,"shares":13678,"price":60,"value":820680.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3310821,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-15T13:31:06.000Z","date":"2020-01-15","kind":"other","acquired":false,"shares":265799,"price":60,"value":15947940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2019, Audentes Therapeutics, Inc. (the \"Company\") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the \"Merger Agreement\") with Astellas Pharma Inc. (\"Astellas\") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas (\"Merger Sub\"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the \"Offer\") and a subsequent merger (the \"Merger\"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the \"Offer Price\") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were canceled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-003430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919120003430/doc4.xml","form_type":"4"}},{"id":3330475,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-27T16:10:55.000Z","date":"2019-12-23","kind":"sale","acquired":false,"shares":1000,"price":59.5963,"value":59596.3,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $59.55 and the highest price at which shares were sold was $59.65."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":13678,"source":{"system":"sec-edgar","filing":"0001209191-19-062016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119062016/doc4.xml","form_type":"4"}},{"id":3330474,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-27T16:10:55.000Z","date":"2019-12-23","kind":"sale","acquired":false,"shares":10000,"price":59.5993,"value":595993.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $59.56 and the highest price at which shares were sold was $59.70.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."}],"balance_after":265799,"source":{"system":"sec-edgar","filing":"0001209191-19-062016","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119062016/doc4.xml","form_type":"4"}},{"id":3406491,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-25T18:11:41.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":1000,"price":32.182,"value":32182.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $31.68 and the highest price at which shares were sold was $32.60."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":14678,"source":{"system":"sec-edgar","filing":"0001209191-19-050729","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119050729/doc4.xml","form_type":"4"}},{"id":3406490,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-25T18:11:41.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":245,"price":32.6628,"value":8002.386,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $32.615 and the highest price at which shares were sold was $32.705."}],"balance_after":275799,"source":{"system":"sec-edgar","filing":"0001209191-19-050729","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119050729/doc4.xml","form_type":"4"}},{"id":3406489,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-25T18:11:41.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":9755,"price":32.149,"value":313613.495,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $31.61 and the highest price at which shares were sold was $32.59.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":276044,"source":{"system":"sec-edgar","filing":"0001209191-19-050729","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119050729/doc4.xml","form_type":"4"}},{"id":3478061,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T16:07:11.000Z","date":"2019-06-24","kind":"sale","acquired":false,"shares":200,"price":39.46,"value":7892.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $39.31 and the highest price at which shares were sold was $39.61"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":15678,"source":{"system":"sec-edgar","filing":"0001209191-19-039082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119039082/doc4.xml","form_type":"4"}},{"id":3478060,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T16:07:11.000Z","date":"2019-06-24","kind":"sale","acquired":false,"shares":800,"price":37.886,"value":30308.8,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $37.37 and the highest price at which shares were sold was $38.30."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":15878,"source":{"system":"sec-edgar","filing":"0001209191-19-039082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119039082/doc4.xml","form_type":"4"}},{"id":3478059,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T16:07:11.000Z","date":"2019-06-24","kind":"sale","acquired":false,"shares":600,"price":39.9975,"value":23998.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $39.88 and the highest price at which shares were sold was $40.41."}],"balance_after":285799,"source":{"system":"sec-edgar","filing":"0001209191-19-039082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119039082/doc4.xml","form_type":"4"}},{"id":3478058,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T16:07:11.000Z","date":"2019-06-24","kind":"sale","acquired":false,"shares":3602,"price":38.1481,"value":137409.4562,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $38.76 and the highest price at which shares were sold was $39.70."}],"balance_after":286399,"source":{"system":"sec-edgar","filing":"0001209191-19-039082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119039082/doc4.xml","form_type":"4"}},{"id":3478057,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-26T16:07:11.000Z","date":"2019-06-24","kind":"sale","acquired":false,"shares":15798,"price":37.6,"value":594004.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $37.39 and the highest price at which shares were sold was $38.34.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (7) to this Form 4."}],"balance_after":290001,"source":{"system":"sec-edgar","filing":"0001209191-19-039082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119039082/doc4.xml","form_type":"4"}},{"id":3576528,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2019-03-27T17:03:31.000Z","date":"2019-03-25","kind":"sale","acquired":false,"shares":558,"price":35.9403,"value":20054.6874,"ownership":{"direct":false,"nature":"By Lange Minor's Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $35.71 and the highest price at which shares were sold was $36.15."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's spouse is the trustee of the Lange Minor's Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-021433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119021433/doc4.xml","form_type":"4"}},{"id":3576527,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-27T17:03:31.000Z","date":"2019-03-25","kind":"sale","acquired":false,"shares":1000,"price":36.0037,"value":36003.7,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $35.63 and the highest price at which shares were sold was $36.19."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":16678,"source":{"system":"sec-edgar","filing":"0001209191-19-021433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119021433/doc4.xml","form_type":"4"}},{"id":3576526,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-27T17:03:31.000Z","date":"2019-03-25","kind":"sale","acquired":false,"shares":300,"price":36.6406,"value":10992.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $36.51 and the highest price at which shares were sold was $36.86."}],"balance_after":305799,"source":{"system":"sec-edgar","filing":"0001209191-19-021433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119021433/doc4.xml","form_type":"4"}},{"id":3576525,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-27T17:03:31.000Z","date":"2019-03-25","kind":"sale","acquired":false,"shares":19700,"price":35.991,"value":709022.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $35.45 and the highest price at which shares were sold was $36.41.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (6) to this Form 4."}],"balance_after":306099,"source":{"system":"sec-edgar","filing":"0001209191-19-021433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119021433/doc4.xml","form_type":"4"}},{"id":3668143,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T17:22:41.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":16200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earlier of (i) the one-year anniversary of the grant date, and (ii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":16200,"derivative":{"exercise_price":24.74,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":16200},"source":{"system":"sec-edgar","filing":"0001209191-19-008667","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919119008667/doc4.xml","form_type":"4"}},{"id":3717573,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-27T17:43:00.000Z","date":"2018-12-24","kind":"sale","acquired":false,"shares":10000,"price":18.4951,"value":184951.0,"ownership":{"direct":false,"nature":"By Asset Management Ventures Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $18.23 and the highest price at which shares were sold was $18.64."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person is a general partner of Asset Management Ventures Fund, L.P. (\"AMVF L.L.P.\"), and has shared voting and dispositive power over the shares held by AMVF L.L.P.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":32343,"source":{"system":"sec-edgar","filing":"0001209191-18-064210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118064210/doc4.xml","form_type":"4"}},{"id":3717572,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2018-12-27T17:43:00.000Z","date":"2018-12-24","kind":"sale","acquired":false,"shares":1000,"price":18.713,"value":18713.0,"ownership":{"direct":false,"nature":"By Lange Minor's Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $18.40 and the highest price at which shares were sold was $18.98."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's spouse is the trustee of the Lange Minor's Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":558,"source":{"system":"sec-edgar","filing":"0001209191-18-064210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118064210/doc4.xml","form_type":"4"}},{"id":3717571,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-27T17:43:00.000Z","date":"2018-12-24","kind":"sale","acquired":false,"shares":1000,"price":18.701,"value":18701.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $18.40 and the highest price at which shares were sold was $18.98."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":17678,"source":{"system":"sec-edgar","filing":"0001209191-18-064210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118064210/doc4.xml","form_type":"4"}},{"id":3717570,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-27T17:43:00.000Z","date":"2018-12-24","kind":"sale","acquired":false,"shares":20000,"price":18.6717,"value":373434.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $18.28 and the highest price at which shares were sold was $19.09.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (6) to this Form 4."}],"balance_after":325799,"source":{"system":"sec-edgar","filing":"0001209191-18-064210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118064210/doc4.xml","form_type":"4"}},{"id":3761069,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T18:34:35.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":4000,"price":22.49,"value":89960.0,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund.  The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund.  The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3555,"source":{"system":"sec-edgar","filing":"0001209191-18-059054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118059054/doc4.xml","form_type":"4"}},{"id":3761068,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T18:34:35.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":20000,"price":22.49,"value":449800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund.  The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund.  The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person."}],"balance_after":345799,"source":{"system":"sec-edgar","filing":"0001209191-18-059054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118059054/doc4.xml","form_type":"4"}},{"id":3807352,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-26T19:00:17.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":10000,"price":37.4536,"value":374536.0,"ownership":{"direct":false,"nature":"By Asset Management Ventures Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $37.00 and the highest price at which shares were sold was $37.675."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The reporting person is a general partner of Asset Management Ventures Fund, L.P. (\"AMVF L.L.P.\"), and has shared voting and dispositive power over the shares held by AMVF L.L.P.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":42343,"source":{"system":"sec-edgar","filing":"0001209191-18-052368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118052368/doc4.xml","form_type":"4"}},{"id":3807351,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2018-09-26T19:00:17.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":1000,"price":37.267,"value":37267.0,"ownership":{"direct":false,"nature":"By Lange Minor's Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $36.93 and the highest price at which shares were sold was $37.62."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person's spouse is the trustee of the Lange Minor's Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":1558,"source":{"system":"sec-edgar","filing":"0001209191-18-052368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118052368/doc4.xml","form_type":"4"}},{"id":3807350,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-26T19:00:17.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":1000,"price":37.266,"value":37266.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $36.93 and the highest price at which shares were sold was $37.62."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's spouse is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":18678,"source":{"system":"sec-edgar","filing":"0001209191-18-052368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118052368/doc4.xml","form_type":"4"}},{"id":3807349,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-26T19:00:17.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":1000,"price":37.2503,"value":37250.3,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $36.84 and the highest price at which shares were sold was $37.61."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":7555,"source":{"system":"sec-edgar","filing":"0001209191-18-052368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118052368/doc4.xml","form_type":"4"}},{"id":3807348,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-26T19:00:17.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":200,"price":37.755,"value":7551.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $37.75 and the highest price at which shares were sold was $37.76."}],"balance_after":365799,"source":{"system":"sec-edgar","filing":"0001209191-18-052368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118052368/doc4.xml","form_type":"4"}},{"id":3807347,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-26T19:00:17.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":19800,"price":37.349,"value":739510.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $36.72 and the highest price at which shares were sold was $37.71.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6) and (9) to this Form 4."}],"balance_after":365999,"source":{"system":"sec-edgar","filing":"0001209191-18-052368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118052368/doc4.xml","form_type":"4"}},{"id":3882309,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":210,"price":41.27,"value":8666.7,"ownership":{"direct":false,"nature":"By Asset Management Ventures Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The reporting person is a general partner of Asset Management Ventures Fund, L.P. (\"AMVF L.L.P.\"), and has shared voting and dispositive power over the shares held by AMVF L.L.P.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":52343,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882308,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":9790,"price":40.8618,"value":400037.022,"ownership":{"direct":false,"nature":"By Asset Management Ventures Fund, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $40.265 and the highest price at which shares were sold was $41.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The reporting person is a general partner of Asset Management Ventures Fund, L.P. (\"AMVF L.L.P.\"), and has shared voting and dispositive power over the shares held by AMVF L.L.P.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":52553,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882307,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":100,"price":41.47,"value":4147.0,"ownership":{"direct":false,"nature":"By Lange Minor's Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The reporting person's domestic partner is the trustee of the Lange Minor's Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":2558,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882306,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":900,"price":40.7356,"value":36662.04,"ownership":{"direct":false,"nature":"By Lange Minor's Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $40.26 and the highest price at which shares were sold was $41.18."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The reporting person's domestic partner is the trustee of the Lange Minor's Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":2658,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882305,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":100,"price":41.46,"value":4146.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":19678,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882304,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":900,"price":40.7916,"value":36712.44,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $40.28 and the highest price at which shares were sold was $41.22."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":19778,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882303,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":1000,"price":40.783,"value":40783.0,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $40.34 and the highest price at which shares were sold was $41.18."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":8555,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882302,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":1140,"price":41.3053,"value":47088.042,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $41.205 and the highest price at which shares were sold was $41.41."}],"balance_after":385799,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3882301,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T18:51:29.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":18860,"price":40.3635,"value":761255.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $40.20 and the highest price at which shares were sold was $41.19.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6), (8) and (10) to this Form 4."}],"balance_after":386939,"source":{"system":"sec-edgar","filing":"0001209191-18-039710","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118039710/doc4.xml","form_type":"4"}},{"id":3900049,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T17:21:36.000Z","date":"2018-06-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earliest of (i) the Company's 2019 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":10000,"derivative":{"exercise_price":38.65,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-18-036738","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118036738/doc4.xml","form_type":"4"}},{"id":3980893,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":6600,"price":29.2655,"value":193152.3,"ownership":{"direct":false,"nature":"By Asset Management Ventures Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.92 and the highest price at which shares were sold was $29.86."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The reporting person is a general partner of Asset Management Ventures Fund, L.P. (\"AMVF L.L.P.\"), and has shared voting and dispositive power over the shares held by AMVF L.L.P.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":62343,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980892,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":18400,"price":28.3514,"value":521665.76,"ownership":{"direct":false,"nature":"By Asset Management Ventures Fund, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $27.91 and the highest price at which shares were sold was $28.89."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The reporting person is a general partner of Asset Management Ventures Fund, L.P. (\"AMVF L.L.P.\"), and has shared voting and dispositive power over the shares held by AMVF L.L.P.  The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes."}],"balance_after":68943,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980891,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":483,"price":29.5695,"value":14282.0685,"ownership":{"direct":false,"nature":"By Lange Minor's Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $29.03 and the highest price at which shares were sold was $29.97."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The reporting person's domestic partner is the trustee of the Lange Minor's Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":3558,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980890,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":517,"price":28.3206,"value":14641.7502,"ownership":{"direct":false,"nature":"By Lange Minor's Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $27.94 and the highest price at which shares were sold was $28.75."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The reporting person's domestic partner is the trustee of the Lange Minor's Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":4041,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980889,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":400,"price":29.5725,"value":11829.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $29.28 and the highest price at which shares were sold was $29.96."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":20678,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980888,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":600,"price":28.38,"value":17028.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $27.94 and the highest price at which shares were sold was $28.88."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":21078,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980887,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":500,"price":29.464,"value":14732.0,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $29.03 and the highest price at which shares were sold was $29.96."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":9555,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980886,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":500,"price":28.284,"value":14142.0,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $27.95 and the highest price at which shares were sold was $28.72."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":10055,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980885,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":1732,"price":29.95,"value":51873.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $29.93 and the highest price at which shares were sold was $29.99."}],"balance_after":405799,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980884,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":6700,"price":29.57,"value":198119.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Of the shares sold in this transaction, 3,432 shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $28.92 and the highest price at which shares were sold was $29.92."}],"balance_after":407531,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":3980883,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-28T21:11:48.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":11568,"price":29,"value":335472.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $27.90 and the highest price at which shares were sold was $28.89.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (8), (9), (11), (12), (14), (15) and (17) to this Form 4."}],"balance_after":414231,"source":{"system":"sec-edgar","filing":"0001209191-18-022003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919118022003/doc4.xml","form_type":"4"}},{"id":4121693,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2017-12-26T19:38:58.000Z","date":"2017-12-22","kind":"sale","acquired":false,"shares":1000,"price":30.8727,"value":30872.7,"ownership":{"direct":false,"nature":"By Lange Minors' Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $30.66 and the highest price at which shares were sold was $31.10."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's domestic partner is the trustee of the Lange Minors' Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":4558,"source":{"system":"sec-edgar","filing":"0001209191-17-067280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117067280/doc4.xml","form_type":"4"}},{"id":4121692,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-26T19:38:58.000Z","date":"2017-12-22","kind":"sale","acquired":false,"shares":1000,"price":30.8581,"value":30858.1,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $30.66 and the highest price at which shares were sold was $31.13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":21678,"source":{"system":"sec-edgar","filing":"0001209191-17-067280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117067280/doc4.xml","form_type":"4"}},{"id":4121691,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-26T19:38:58.000Z","date":"2017-12-22","kind":"sale","acquired":false,"shares":1000,"price":30.9019,"value":30901.9,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $30.66 and the highest price at which shares were sold was $31.13."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":10555,"source":{"system":"sec-edgar","filing":"0001209191-17-067280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117067280/doc4.xml","form_type":"4"}},{"id":4121690,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-26T19:38:58.000Z","date":"2017-12-22","kind":"sale","acquired":false,"shares":15000,"price":30.8773,"value":463159.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $30.44 and the highest price at which shares were sold was $31.20.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (6) to this Form 4."}],"balance_after":425799,"source":{"system":"sec-edgar","filing":"0001209191-17-067280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117067280/doc4.xml","form_type":"4"}},{"id":4189139,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-10-10T18:04:19.000Z","date":"2017-10-08","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the shares upon the earliest of (i) the Company's 2018 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date."}],"balance_after":9000,"derivative":{"exercise_price":26.01,"expiration_date":"2027-10-08","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-17-056526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117056526/doc4.xml","form_type":"4"}},{"id":4199152,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":200,"price":29.245,"value":5849.0,"ownership":{"direct":false,"nature":"By Lange Minors' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $29.24 and the highest price at which shares were sold was $29.25."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The reporting person's domestic partner is the trustee of the Lange Minors' Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":5558,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4199151,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":1800,"price":28.1377,"value":50647.86,"ownership":{"direct":false,"nature":"By Lange Minors' Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.00 and the highest price at which shares were sold was $28.42."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The reporting person's domestic partner is the trustee of the Lange Minors' Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":5758,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4199150,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":200,"price":29.24,"value":5848.0,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":22678,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4199149,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":1800,"price":28.1419,"value":50655.42,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.00 and the highest price at which shares were sold was $28.45."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":22878,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4199148,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":300,"price":29.26,"value":8778.0,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $29.24 and the highest price at which shares were sold was $29.29."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":11555,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4199147,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":1700,"price":28.1235,"value":47809.95,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.00 and the highest price at which shares were sold was $28.36."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":11855,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4199146,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":756,"price":29.3188,"value":22165.0128,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $29.00 and the highest price at which shares were sold was $29.52."}],"balance_after":440799,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4199145,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T17:47:10.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":4244,"price":28.3106,"value":120150.1864,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $27.92 and the highest price at which shares were sold was $28.86.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (5), (6), (8) and (10) to this Form 4."}],"balance_after":441555,"source":{"system":"sec-edgar","filing":"0001209191-17-054439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054439/doc4.xml","form_type":"4"}},{"id":4201609,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":359,"price":28.8757,"value":10366.3763,"ownership":{"direct":false,"nature":"By Lange Minors' Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.82 and the highest price at which shares were sold was $28.96."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The reporting person's domestic partner is the trustee of the Lange Minors' Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":7558,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4201608,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":641,"price":28.0664,"value":17990.5624,"ownership":{"direct":false,"nature":"By Lange Minors' Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $27.60 and the highest price at which shares were sold was $28.49."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The reporting person's domestic partner is the trustee of the Lange Minors' Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":7917,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4201607,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":364,"price":28.8478,"value":10500.5992,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.75 and the highest price at which shares were sold was $28.96."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":24678,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4201606,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":636,"price":28.0607,"value":17846.6052,"ownership":{"direct":false,"nature":"By Amygdala Lange Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $27.60 and the highest price at which shares were sold was $28.49."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reporting person's domestic partner is the trustee of the Amygdala Lange Trust.  The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":25042,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4201605,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":400,"price":28.8874,"value":11554.96,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.80 and the highest price at which shares were sold was $29.03."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":13555,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4201604,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":600,"price":27.9933,"value":16795.98,"ownership":{"direct":false,"nature":"By Adrienne M. MacMillan Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $27.75 and the highest price at which shares were sold was $28.50."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reporting person's domestic partner is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":13955,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4201603,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":7594,"price":28.7632,"value":218427.7408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $28.30 and the highest price at which shares were sold was $29.04."}],"balance_after":445799,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4201602,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-26T17:44:54.000Z","date":"2017-09-25","kind":"sale","acquired":false,"shares":7406,"price":27.8482,"value":206243.7692,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price.  The lowest price at which shares were sold was $27.28 and the highest price at which shares were sold was $28.27.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (6), (7), (9), (10) and (12) to this Form 4."}],"balance_after":453393,"source":{"system":"sec-edgar","filing":"0001209191-17-054041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117054041/doc4.xml","form_type":"4"}},{"id":4271134,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-28T16:42:38.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":7176,"price":20.5878,"value":147738.0528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $20.21 and the highest price at which shares were sold was $20.90."}],"balance_after":460799,"source":{"system":"sec-edgar","filing":"0001209191-17-042143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117042143/doc4.xml","form_type":"4"}},{"id":4271133,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-28T16:42:38.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":2824,"price":19.5212,"value":55127.8688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the average weighted sale price. The lowest price at which shares were sold was $19.18 and the highest price at which shares were sold was $20.17."}],"balance_after":467975,"source":{"system":"sec-edgar","filing":"0001209191-17-042143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117042143/doc4.xml","form_type":"4"}},{"id":4271132,"issuer":{"id":122788,"kind":"organization","name":"Audentes Therapeutics, Inc."},"owners":[{"id":17051,"kind":"person","name":"LANGE LOUIS G","position":1,"cik":"0001238401","reported_name":"LANGE LOUIS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-28T16:42:38.000Z","date":"2017-06-26","kind":"sale","acquired":false,"shares":5000,"price":18.7633,"value":93816.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the average weighted sale price.  The lowest price at which shares were sold was $18.165 and the highest price at which shares were sold was $19.14.  The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."}],"balance_after":470799,"source":{"system":"sec-edgar","filing":"0001209191-17-042143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628738/000120919117042143/doc4.xml","form_type":"4"}}],"next_cursor":"2017-06-28T16:42:38.000000Z,4271132"}